Patents by Inventor Thierry Sifferlen

Thierry Sifferlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidine derivatives as PGE2 receptor modulators
    Patent number: 11839613
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: December 12, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Phenyl derivatives as PGE2 receptor modulators
    Patent number: 11712438
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 1, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • N-SUBSTITUTED INDOLE DERIVATIVES
    Publication number: 20230165859
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: November 27, 2022
    Publication date: June 1, 2023
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Pyrimidine derivatives
    Patent number: 11446298
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 20, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20220175775
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 9, 2022
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
    Patent number: 11325899
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 10, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • N-substituted indole derivatives as PGE2 receptor modulators
    Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • Benzimidazole-proline derivatives
    Patent number: 11040966
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 22, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20210115031
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20210113559
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20200289507
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 17, 2020
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20200179383
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: June 11, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • PYRIMIDINE DERIVATIVES
    Publication number: 20200108068
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • N-SUBSTITUTED INDOLE DERIVATIVES
    Publication number: 20200069686
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20190263797
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi Williams
  • Benzimidazole-proline derivatives
    Patent number: 10329287
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 25, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 10023560
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 17, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
    Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Use of benzimidazole-proline derivatives
    Patent number: 9914721
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Catherine Roch, Christine Brotschi, Markus Gude, Bibia Heidmann, Francois Jenck, Thierry Sifferlen, Michel Steiner, Jodi T. Williams
  • CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
    Publication number: 20180002317
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS